Sept 29 (Reuters) - Genmab A/S:: *GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL *GENMAB A/S - TO BUY MERUS FOR USD 8.0 BILLION *GENMAB A/S - DEAL EXPECTED TO BE ACCRETIVE TO EBITDA BY 2029 *GENMAB A/S - USD 97.00 PER SHARE REPRESENTS 41% PREMIUM OVER CLOSING PRICE
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.